Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment.
| Autor: | Lim YW; GigaGen, Inc., One Tower Place, Suite 750, South San Francisco, CA, 94080, USA., Coles GL; GigaGen, Inc., One Tower Place, Suite 750, South San Francisco, CA, 94080, USA., Sandhu SK; GigaGen, Inc., One Tower Place, Suite 750, South San Francisco, CA, 94080, USA., Johnson DS; GigaGen, Inc., One Tower Place, Suite 750, South San Francisco, CA, 94080, USA., Adler AS; GigaGen, Inc., One Tower Place, Suite 750, South San Francisco, CA, 94080, USA. aadler@gigagen.com., Stone EL; GigaGen, Inc., One Tower Place, Suite 750, South San Francisco, CA, 94080, USA. estone@gigagen.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMC biology [BMC Biol] 2021 May 25; Vol. 19 (1), pp. 107. Date of Electronic Publication: 2021 May 25. |
| DOI: | 10.1186/s12915-021-01034-z |
| Abstrakt: | Background: The anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and efficacy of anti-PD-1/PD-L1 therapy. TGF-β has been shown to contribute to T cell exclusion, and anti-TGF-β improves anti-PD-L1 efficacy in vivo. However, TGF-β inhibition has frequently been shown to induce toxicity in the clinic, and the clinical efficacy of combination PD-L1 and TGF-β blockade has not yet been proven. To identify strategies to overcome resistance to PD-L1 blockade, the transcriptional programs associated with PD-L1 and/or TGF-β blockade in the tumor microenvironment should be further elucidated. Results: We used single-cell RNA sequencing in a mouse model to characterize the transcriptomic effects of PD-L1 and/or TGF-β blockade on nearly 30,000 single cells in the tumor and surrounding microenvironment. Combination treatment led to upregulation of immune response genes, including multiple chemokine genes such as CCL5, in macrophages, and downregulation of extracellular matrix genes in fibroblasts. Analysis of publicly available tumor transcriptome profiles showed that the chemokine CCL5 was strongly associated with immune cell infiltration in various human cancers. Further investigation with in vivo models showed that intratumorally administered CCL5 enhanced cytotoxic lymphocytes and the anti-tumor activity of anti-PD-L1. Conclusions: Taken together, our data could be leveraged translationally to complement or find alternatives to anti-PD-L1 plus anti-TGF-β combination therapy, for example through companion biomarkers, and/or to identify novel targets that could be modulated to overcome resistance. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|